1-4 of 4
Michael A. Morgan, Ph.D.
Close
Sort by
Journal Articles

Favorable Prognostic Impact of WT1 SNP rs16754 in Cytogenetically Normal AML Independent of MN1, BAALC, and ERG Expression.

Frederik Damm, M.D., Juergen Krauter, Iyas Hamwi, Michael A. Morgan, Ph.D., Gudrun Goehring, Brigitte Schlegelberger, MD, Arnold Ganser, MD, Michael Heuser, MD
Journal: Blood
Blood (2009) 114 (22): 1622.
https://doi.org/10.1182/blood.V114.22.1622.1622
Published: 2009
Journal Articles

A Novel Proteomic Approach to Define Leukemia Cell Resistance to Farnesyltransferase Inhibitors.

Fredrick O. Onono, Ph.D., Michael A. Morgan, Ph.D., H. Peter Spielmann, Ph.D., Douglas A Andres, Ph.D., Michaela Scherr, Ph.D., Letizia Venturini, Ph.D., Iris Dallman, Arnold Ganser, MD, Christoph WM Reuter, M.D., Ph.D.
Journal: Blood
Blood (2009) 114 (22): 3761.
https://doi.org/10.1182/blood.V114.22.3761.3761
Published: 2009
Journal Articles

The Farnesyltransferase Inhibitor (FTI) L-778,123 Displays Promising Anti-Leukemia Activity

Fredrick O. Onono, Michael A. Morgan, Ph.D., Arnold Ganser, M.D., Ph.D., Christoph W. M. Reuter, M.D., Ph.D.
Journal: Blood
Blood (2008) 112 (11): 2627.
https://doi.org/10.1182/blood.V112.11.2627.2627
Published: 2008
Journal Articles

Targeting RAS Signaling in Multiple Myeloma (MM): Synergistic Inhibition by Co-Treatment with the MEK Inhibitor U0126 and Prenylation Inhibitors.

Christoph W.M. Reuter, MD/Ph.D., Michael A. Morgan, Ph.D., Tarkan Sebil, Arnold Ganser, MD/Ph.D.
Journal: Blood
Blood (2004) 104 (11): 3398.
https://doi.org/10.1182/blood.V104.11.3398.3398
Published: 2004